Your browser doesn't support javascript.
loading
GLUT1 overexpression in CAR-T cells induces metabolic reprogramming and enhances potency.
Guerrero, Justin A; Klysz, Dorota D; Chen, Yiyun; Malipatlolla, Meena; Lone, Jameel; Fowler, Carley; Stuani, Lucille; May, Audre; Bashti, Malek; Xu, Peng; Huang, Jing; Michael, Basil; Contrepois, Kévin; Dhingra, Shaurya; Fisher, Chris; Svensson, Katrin J; Davis, Kara L; Kasowski, Maya; Feldman, Steven A; Sotillo, Elena; Mackall, Crystal L.
Affiliation
  • Guerrero JA; Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, tanford, CA, USA.
  • Klysz DD; Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, tanford, CA, USA.
  • Chen Y; Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, tanford, CA, USA.
  • Malipatlolla M; Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, tanford, CA, USA.
  • Lone J; Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
  • Fowler C; Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, tanford, CA, USA.
  • Stuani L; Division of Pediatric Hematology/Oncology/Stem Cell Transplant and Regenerative Medicine, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA.
  • May A; Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, tanford, CA, USA.
  • Bashti M; Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, tanford, CA, USA.
  • Xu P; Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, tanford, CA, USA.
  • Huang J; Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, tanford, CA, USA.
  • Michael B; Metabolic Health Center, Stanford University School of Medicine, Stanford, CA, USA.
  • Contrepois K; Metabolic Health Center, Stanford University School of Medicine, Stanford, CA, USA.
  • Dhingra S; Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, tanford, CA, USA.
  • Fisher C; Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, tanford, CA, USA.
  • Svensson KJ; Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
  • Davis KL; Stanford Diabetes Research Center, Stanford University School of Medicine, Stanford, CA, USA.
  • Kasowski M; Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA, USA.
  • Feldman SA; Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, tanford, CA, USA.
  • Sotillo E; Division of Pediatric Hematology/Oncology/Stem Cell Transplant and Regenerative Medicine, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA.
  • Mackall CL; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Nat Commun ; 15(1): 8658, 2024 Oct 06.
Article in En | MEDLINE | ID: mdl-39370422
ABSTRACT
The intensive nutrient requirements needed to sustain T cell activation and proliferation, combined with competition for nutrients within the tumor microenvironment, raise the prospect that glucose availability may limit CAR-T cell function. Here, we seek to test the hypothesis that stable overexpression (OE) of the glucose transporter GLUT1 in primary human CAR-T cells would improve their function and antitumor potency. We observe that GLUT1OE in CAR-T cells increases glucose consumption, glycolysis, glycolytic reserve, and oxidative phosphorylation, and these effects are associated with decreased T cell exhaustion and increased Th17 differentiation. GLUT1OE also induces broad metabolic reprogramming associated with increased glutathione-mediated resistance to reactive oxygen species, and increased inosine accumulation. When challenged with tumors, GLUT1OE CAR-T cells secrete more proinflammatory cytokines and show enhanced cytotoxicity in vitro, and demonstrate superior tumor control and persistence in mouse models. Our collective findings support a paradigm wherein glucose availability is rate limiting for effector CAR-T cell function and demonstrate that enhancing glucose availability via GLUT1OE could augment antitumor immune function.
Subject(s)

Full text: 1 Database: MEDLINE Main subject: T-Lymphocytes / Glucose Transporter Type 1 / Glucose / Glycolysis Limits: Animals / Humans Language: En Journal: Nat Commun / Nature communications Journal subject: BIOLOGIA / CIENCIA Year: 2024 Type: Article Affiliation country: United States

Full text: 1 Database: MEDLINE Main subject: T-Lymphocytes / Glucose Transporter Type 1 / Glucose / Glycolysis Limits: Animals / Humans Language: En Journal: Nat Commun / Nature communications Journal subject: BIOLOGIA / CIENCIA Year: 2024 Type: Article Affiliation country: United States